Hypersensitivity to Aurora Kinase Inhibitors in Cells Resistant against Platinum- Containing Anticancer Agents
- 7 February 2014
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Anti-Cancer Agents in Medicinal Chemistry
- Vol. 14 (7) , 1042-1050
Abstract
The aurora kinases are serine/threonine kinases that are essential for mitosis and contribute to tumorigenesis. Therefore, aurora kinases hold promise for molecularly targeted therapy. In the present study, we demonstrated that aurora B kinase (AURKB) is overexpressed in both cisplatin- and oxaliplatin-resistant cells. Downregulation of AURKB sensitized cells to both cisplatin and oxaliplatin, but not to paclitaxel, 5-FU or hydrogen peroxide. Interestingly, we found that both cisplatin- and oxaliplatin-resistant cells were hypersensitive to the AURKB specific inhibitors, AZD1152 HQPA and ZM447439, suggesting that both cisplatin- and oxaliplatinresistant cells develop an addiction to AURKB. These data provide evidence that aurora kinase inhibitors can overcome both cisplatin and oxaliplatin resistance. Therefore, AURKB inhibitors could offer potential benefits if used after first-line platinum-based chemotherapy.Keywords
This publication has 18 references indexed in Scilit:
- Aurora kinase inhibitors: Progress towards the clinicInvestigational New Drugs, 2012
- Molecular mechanisms of cisplatin resistanceOncogene, 2011
- Aurora kinase A critically contributes to the resistance to anti-cancer drug cisplatin in JAK2 V617F mutant-induced transformed cellsFEBS Letters, 2011
- Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancerBritish Journal of Cancer, 2011
- Ets regulates peroxiredoxin1 and 5 expressions through their interaction with the high‐mobility group protein B1Cancer Science, 2008
- Tip60 Is Regulated by Circadian Transcription Factor Clock and Is Involved in Cisplatin ResistanceJournal of Biological Chemistry, 2008
- ZNF143 interacts with p73 and is involved in cisplatin resistance through the transcriptional regulation of DNA repair genesOncogene, 2007
- A Genome Scale Location Analysis of Human Staf/ZNF143-binding Sites Suggests a Widespread Role for Human Staf/ZNF143 in Mammalian PromotersJournal of Biological Chemistry, 2006
- Transcription factors and drug resistanceEuropean Journal of Cancer, 2005
- Cisplatin: mode of cytotoxic action and molecular basis of resistanceOncogene, 2003